Bioregulator peptides are a family of very short peptides, mostly two to four amino acids long, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Each was derived from, or designed after, a polypeptide extract of a particular animal tissue, such as the pineal gland (Epitalon, Ala-Glu-Asp-Gly) or the thymus (Vilon, Lys-Glu). The group proposes that these peptides enter the cell nucleus and bind DNA and histones, changing gene expression; that model rests largely on in-vitro and computational work from the originating group.
This article sets out what the bioregulator peptides are, where they came from, their verified chemical identities, the proposed mechanism and the evidence behind it, and the practical chemistry of handling such short, acidic peptides in the laboratory.
From tissue extracts to synthetic short peptides
The bioregulator program began with extracts, not with synthetic sequences. Khavinson's group, working with V. G. Morozov and V. N. Anisimov, prepared polypeptide fractions from animal organs and studied them in cell cultures and in rodents and insects. The best known are epithalamin, an extract of the pineal gland, and thymalin, an extract of the thymus. A 1994 paper by Anisimov, Khavinson and Morozov in the Annals of the New York Academy of Sciences already reviewed twenty years of work on epithalamin.
Extracts are mixtures, and a mixture is hard to characterize or reproduce. The group's next step was to identify short peptides that could stand in for each extract. According to a 2025 review of Epitalon in the International Journal of Molecular Sciences, the tetrapeptide Ala-Glu-Asp-Gly was designed on the basis of the amino acid composition of epithalamin and synthesized before it had been found in the natural extract; its presence in a pineal gland extract was reported only in 2017.
Other short peptides followed the same logic: a sequence associated with a tissue extract, synthesized chemically and then tested in that tissue's cell types. A 2021 systematic review by Khavinson and colleagues in Molecules lists more than ten of them, mostly two to four residues long.
The main bioregulator peptides
The identities below are from PubChem records. Names are the trade or trivial names used in the literature; the tissue column records the extract or cell type each peptide has been associated with by its developers, not a demonstrated effect.
| Name | Sequence (one-letter) | Length | Molecular formula | Molecular weight (g/mol) | CAS number | PubChem CID | Associated extract or tissue |
|---|---|---|---|---|---|---|---|
| Epitalon (Epithalon) | Ala-Glu-Asp-Gly (AEDG) | 4 | C14H22N4O9 | 390.35 | 307297-39-8 | 219042 | Pineal gland (epithalamin) |
| Pinealon | Glu-Asp-Arg (EDR) | 3 | C15H26N6O8 | 418.40 | 175175-23-2 | 10273502 | Brain tissue |
| Cartalax | Ala-Glu-Asp (AED) | 3 | C12H19N3O8 | 333.29 | not confirmed | 87815447 | Cartilage |
| Vilon | Lys-Glu (KE) | 2 | C11H21N3O5 | 275.30 | 45234-02-4 | 7010502 | Thymus (thymalin) |
| Thymogen (oglufanide) | Glu-Trp (EW) | 2 | C16H19N3O5 | 333.34 | 38101-59-6 | 100094 | Thymus (thymalin) |
| Thymalin | Polypeptide complex | Mixture | Not a single compound | — | — | — | Thymus extract |
Several more appear in the 2021 review, including Bronchogen (Ala-Glu-Asp-Leu, AEDL), associated with lung cells, and Testagen (Lys-Glu-Asp-Gly, KEDG), associated with male reproductive tissue, along with KED and KEDW.
Two features stand out in the sequences. First, they are very short: the longest in the main table has four residues. Second, they are dominated by acidic residues, glutamic acid and aspartic acid, with lysine or arginine appearing in some. At neutral pH most of them carry a net negative charge, which affects both how they dissolve and how they might interact with the positively charged histone proteins discussed below.
Thymalin is different
Thymalin is not a short peptide but the extract itself: a 2020 paper from the group describes it as "a polypeptide complex isolated from the thymus." It is the only entry in the table that has no single structure, formula or molecular weight. A 2023 study in the International Journal of Molecular Sciences examined two dipeptides, KE and EW, as components of the thymalin preparation, using molecular docking against DNA, bioinformatic analysis and a model of cytokine release in human peripheral blood mononuclear cells stimulated with bacterial lipopolysaccharide. Anhydrolabs lists Thymalin in its catalog.
The proposed mechanism: short peptides and DNA
The central claim of the bioregulator literature is that short peptides act on gene expression directly, rather than by binding a cell-surface receptor in the way a peptide hormone does. The 2021 review summarizes it this way: short peptides of two to seven residues can enter the nucleus and nucleolus and interact with nucleosomes, histone proteins, and single- and double-stranded DNA. The main lines of evidence are as follows.
Nuclear entry. In a 2011 study in Biochemistry (Moscow), HeLa cells incubated with fluorescein-labeled Epitalon, Pinealon and Testagen showed fluorescence in the cytoplasm, the nucleus and the nucleolus.
Sequence-selective DNA binding. In the same study, the peptides quenched the fluorescence of labeled oligonucleotides to different degrees depending on sequence. Epitalon, Pinealon and Bronchogen bound preferentially to sequences containing CNG sites, the targets of cytosine methylation in eukaryotic DNA; Epitalon, Testagen and Pinealon favored CAG-containing sequences, while Bronchogen favored CTG. The authors reported that binding was sensitive to cytosine methylation.
Histone binding. The 2021 review reports that AEDG, EDR, AEDL, KEDG, AEDR and KEDW bind fluorescently tagged wheat histones H1, H2B, H3 and H4, and that AEDG interacts with the H1/6 and H1/3 histone subtypes.
Modeling. A 2005 paper used a complementary-binding model to propose that Epitalon binds the base-pair block ATTTTC in the DNA major groove, and noted that this block recurs in the promoter region of telomerase.
How strong is that evidence?
The model is specific and testable, but most of the supporting data comes from the originating group and its collaborators, and much of it is in-vitro binding, fluorescence or docking work. The small molecular size also raises an obvious question for any in-vivo reading: dipeptides and tripeptides are ordinary substrates for the peptidases present in blood and tissues. For a laboratory, the mechanism is best treated as a hypothesis with a defined set of experiments behind it, not an established pathway.
Independent work does exist for Epitalon. A 2025 study from Brunel University London, published in Biogerontology, treated the breast cancer cell lines 21NT and BT474 and normal epithelial and fibroblast cells with Epitalon and measured hTERT mRNA, telomerase activity and telomere length by qPCR and immunofluorescence. The authors reported telomere extension associated with hTERT and telomerase upregulation in the normal cells, and extension through the alternative lengthening of telomeres (ALT) pathway in the cancer lines.
Research models for each peptide
The table summarizes the experimental systems described in the sources cited here. It lists what was studied and measured, not outcomes in any organism.
| Peptide | Systems studied | What was measured |
|---|---|---|
| Epitalon (AEDG) | HeLa cells; human fibroblasts; breast cancer and normal epithelial cell lines; rodents and insects (epithalamin and AEDG) | Nuclear uptake, DNA and histone binding, hTERT expression, telomerase activity, telomere length |
| Pinealon (EDR) | Rat cerebellar granule cells, neutrophils, PC12 pheochromocytoma cells | Reactive oxygen species accumulation, necrotic cell death, ERK 1/2 activation, distribution of cells across division phases |
| Cartalax (AED) | Human skin fibroblasts during replicative aging in culture | Expression of sirtuin-1, sirtuin-6 and collagen I |
| Vilon (KE) | Human skin fibroblasts; peripheral blood mononuclear cells; docking models | IL-1, NF-kB, TGF-beta and sirtuin-6 expression; cytokine release; DNA binding |
| Thymalin | Human hematopoietic stem cells | CD44, CD117 and CD28 expression during differentiation |
A few details are worth noting. The 2011 Pinealon study reported that restriction of reactive oxygen species leveled off at lower concentrations while its effect on cell division continued at higher ones, which the authors read as evidence of a second, genome-level action beyond an antioxidant one. The 2020 Cartalax study compared AED directly with KE in the same fibroblast model and found they affected different sets of markers. In the 2020 Thymalin study, CD44 and CD117 expression fell two- to threefold and CD28 expression rose 6.8-fold, which the authors interpreted as differentiation toward mature T lymphocytes.
Regulatory status
None of these peptides is an FDA-approved drug; none appears in the FDA's Drugs@FDA database. The originating group's papers describe Thymalin as a peptide drug and refer to several of the short peptides as preparations developed in Russia. For laboratories in the United States they are research reagents, and Anhydrolabs supplies them for in-vitro research only, not for human or veterinary diagnosis, treatment, or consumption.
Handling short acidic peptides in the lab
The bioregulator peptides are chemically simple compared with most research peptides, but their composition has consequences.
Solubility. Rich in glutamic and aspartic acid and free of hydrophobic stretches, most of them dissolve readily in water or aqueous buffer. The free acid form can lower the pH of an unbuffered solution slightly, so a buffered diluent gives more reproducible stock solutions for in-vitro assays.
Aspartic acid chemistry. Epitalon, Pinealon and Cartalax all contain aspartic acid, and Epitalon ends in Asp-Gly, the sequence most prone to aspartimide formation during synthesis and to isoaspartate formation in solution. The article on how peptides are made explains why that motif needs care, and it is one reason to keep solutions cold and use them promptly.
Analysis. At two to four residues, these peptides have small masses (275 to 418 g/mol for those in the table) and, except for the tryptophan in EW, no aromatic residue to absorb at 280 nm. HPLC detection therefore relies on the absorbance of the peptide bond itself at low wavelengths, as described in the peptide bond. Very short, polar peptides can also elute early on reversed-phase columns, so methods are often adjusted to retain them.
Storage. As with any peptide, the lyophilized powder is the stable form. Anhydrolabs lists Epithalon, Pinealon and Cartalax in its catalog; its peptides are supplied as lyophilized powder in vacuum-sealed vials, and many as 10-vial kits. A dedicated profile of Epithalon covers that tetrapeptide in more depth, and the broader question of what peptides are is covered separately.


